Assembly Biosciences Inc (ASMB) Expected to Announce Quarterly Sales of $3.21 Million
Equities analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to report $3.21 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Assembly Biosciences’ earnings, with estimates ranging from $3.20 million to $3.22 million. Assembly Biosciences posted sales of $2.66 million during the same quarter last year, which suggests a positive year over year growth rate of 20.7%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 7th.
According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $13.05 million for the current fiscal year, with estimates ranging from $12.00 million to $13.60 million. For the next financial year, analysts expect that the business will post sales of $25.90 million per share, with estimates ranging from $12.87 million to $63.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.42). The business had revenue of $3.22 million during the quarter, compared to analyst estimates of $3.30 million. Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%.
ASMB stock traded up $0.51 during mid-day trading on Monday, reaching $38.35. The company’s stock had a trading volume of 75,934 shares, compared to its average volume of 227,848. The company has a market cap of $933.38 million, a price-to-earnings ratio of -15.91 and a beta of 0.86. Assembly Biosciences has a fifty-two week low of $25.91 and a fifty-two week high of $67.36.
In related news, Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $38.50, for a total transaction of $38,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Derek A. Small acquired 2,400 shares of the stock in a transaction that occurred on Thursday, July 19th. The shares were bought at an average cost of $41.48 per share, with a total value of $99,552.00. Following the transaction, the chief executive officer now directly owns 668,091 shares in the company, valued at approximately $27,712,414.68. The disclosure for this purchase can be found here. Corporate insiders own 18.20% of the company’s stock.
Several large investors have recently bought and sold shares of ASMB. TIAA CREF Investment Management LLC boosted its position in shares of Assembly Biosciences by 46.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock worth $3,273,000 after purchasing an additional 23,064 shares during the period. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $326,000. Rhumbline Advisers boosted its position in shares of Assembly Biosciences by 17.8% during the 1st quarter. Rhumbline Advisers now owns 15,125 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 2,289 shares during the period. Victory Capital Management Inc. boosted its position in shares of Assembly Biosciences by 263.7% during the 1st quarter. Victory Capital Management Inc. now owns 122,580 shares of the biopharmaceutical company’s stock worth $6,024,000 after purchasing an additional 88,880 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Assembly Biosciences by 12.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 35,200 shares of the biopharmaceutical company’s stock worth $1,730,000 after purchasing an additional 3,800 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Featured Story: Fundamental Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.